PolyPid Ltd PYPD

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

CEO

Ms. Dikla Czaczkes Akselbrad

Founded

2008

Employees

59

Sector

Healthcare

Industry

Biotechnology

Headquarters

Petah TikvaIsrael

High Today

$2.70

Low Today

$2.59

Open Today

$2.63

Volume Today

11,200.0

52 Week High

$5.09

52 Week Low

$2.30

Average Volume

9,719